Drug or treatment
Ezabenlimab clinical trials
As of November 12, 2026, Find a Trial lists 4 clinical trials of Ezabenlimab that are recruiting, at sites in 9 countries (most in Japan (3), Spain (3), United States (3)). By phase: Phase 1 (4). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 9Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Testing different doses of BI 3968621 alone or with ezabenlimab in adults with advanced cancer | Phase 1 | Sarasota, Florida and 9 other locations | Recruiting | Oct 1, 2026 |
| Testing how well different doses of BI 3819026 can be tolerated alone and with ezabenlimab in advanced cancer | Phase 1 | New Haven, Connecticut and 8 other locations | Recruiting | May 26, 2026 |
| Testing a new cancer treatment with BI 1703880 and ezabenlimab | Phase 1 | Los Angeles, California and 20 other locations | Recruiting | Jul 25, 2022 |
| Intracranial NK-92 cell injections plus IV ezabenlimab for recurrent HER2‑positive glioblastoma | Phase 1 | Heidelberg, Baden-Wurttemberg and 4 other locations | Recruiting | Dec 27, 2017 |
All recruiting trials (4)
-
Testing different doses of BI 3968621 alone or with ezabenlimab in adults with advanced cancer
This study tests whether BI 3968621, alone or with ezabenlimab, can be given safely at different doses to adults with advanced solid tumors and whether it can slow or shrink tumors.
-
Testing how well different doses of BI 3819026 can be tolerated alone and with ezabenlimab in advanced cancer
This study tests whether varying doses of BI 3819026 can be tolerated by adults with advanced solid cancers, both by itself and in combination with ezabenlimab.
-
Testing a new cancer treatment with BI 1703880 and ezabenlimab
This study is testing a new cancer treatment combining two medications to see if they can help adults with advanced tumors that haven’t responded to other treatments.
-
Intracranial NK-92 cell injections plus IV ezabenlimab for recurrent HER2‑positive glioblastoma
This trial will test whether injecting engineered NK-92 immune cells into the brain together with intravenous ezabenlimab is safe and shows signs of benefit in adults with recurrent HER2‑positive glioblastoma.
Quick answers
How many clinical trials of Ezabenlimab are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 9 countries. The most sites are in Japan (3 trials), Spain (3 trials), United States (3 trials), South Korea (1 trial), Taiwan (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 4. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.